CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma: Durvalumab (trade name: Imfinzi) is a human IgG1 anti-PD-L1 monoclonal antibody, and clinical trials are currently underway investigating the use of durvalumab alone or in combination with lenalidomide for the treatment of R/R PTCL (NCT03011814), in combination with pramipexole, romidepsin, and/or azacitidine (NCT03161223) for the treatment of T-cell lymphoma.